Challenges in COVID-19 Vaccination

  • Lectures & Discussions
  • Online
Leopoldina International Virtual Panel Discussion in Cooperation with the Indian National Science Academy
Bottles coronavirus vaccine. sars-cov-2 / COVID-19
  • Date
  • Location Online

Effective and secure vaccines against the novel coronavirus SARS-CoV-2 – alongside better treatments – are the most promising way out of the COVID-19 pandemic. Several vaccine candidates have already received use authorization, many more are under development and are being tested in clinical trials. However, there are still huge challenges ahead: Even after approval, vaccines will not be available on a large scale immediately. Challenges range from manufacturing bottlenecks and complex logistic requirements like consistent cold storage to the provision of sufficient vaccination facilities with an adequately trained health care workforce. Challenges like vaccine prioritization or inequities in terms of global allocation must be met. How to build public trust to reach the necessary level of immunity in the population or how to deal with potential misinformation about COVID-19 and vaccines are other questions that need to be addressed.

This virtual panel discussion explores approaches to address these challenges in COVID-19 vaccination from a scientific perspective. The event is jointly organized by the German National Academy of Sciences Leopoldina and the Indian National Science Academy (INSA).

INSA and Leopoldina welcome the following experts to the podium:

  • Professor Regina T. Riphahn, PhD, Vice-President of German National Academy of Sciences Leopoldina (host)
  • Professor Gagandeep Kang, PhD, Chair of the Immunization Technical Advisory Group for the WHO South East Asian Region, Fellow of the Indian National Science Academy (INSA)
  • Richard Hatchett, MD, Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations (CEPI)
  • Professor Heidi Larson, PhD, Director of The Vaccine Confidence Project, London School of Hygiene & Tropical Medicine, United Kingdom
  • Florian von der Mülbe, MBA, PhD, Chief Production Officer and Co-Founder of CureVac, Germany

This panel discussion is part of the Leopoldina International Virtual Panel Series. In July 2020, the Leopoldina launched a virtual format for global scientific exchange: Leopoldina International – a series of online panels organized by Leopoldina’s International Relations Department in cooperation with its international partners. Leopoldina International offers a virtual room for the global scientific community to convene and for the interested public to join the dialogue with scientists. Previous topics have been “COVID-19 and Multimorbidity: How to Deal with Multiple Infectious Diseases in Parallel?”, “The Hidden Crisis: Mental Health in Times of COVID-19” and “Contact Tracing Apps: Promising Tool in the Fight Against COVID-19?”.

Further Information

Flyer (PDF)

Speakers Profiles (PDF)

Contact

Dr Ruth Narmann
Deputy Head, International Relations Department
German National Academy of Sciences Leopoldina
Tel. +49 (0)30 203 8997 432
Email: ruth.narmann(at)leopoldina.org

Christian Weidlich
Senior Officer, International Relations Department
German National Academy of Sciences Leopoldina
Tel. +49 (0)345 472 39 868
Email: christian.weidlich(at)leopoldina.org

Further events in the series

Contact Tracing Apps (15 July 2020)

Mental Health in Times of COVID-19 (28 September 2020)

COVID-19 and Multimorbidity (26 November 2020)

Video recording of the event

Download video (mp4)

The Leopoldina uses cookies

We use cookies on our website. Some of them are necessary (functional cookies), while others are not necessary but help us to improve our online offering and operate it economically.

You can consent to the use of non-essential cookies by clicking on the "Accept all" button or by clicking on individual settings and agreeing to them by clicking on "Accept selection".

You can access these settings at any time and deselect cookies at a later date.

Functional

These cookies are technically necessary in order to provide the following core functionalities of the website:

  • Display of the website
  • Anonymisation of IP addresses within log files
  • Status cookie consent
Comfort

In addition to necessary cookies, we also use cookies to make your use of the website more pleasant. If you accept these cookies, external media will be loaded without your further consent.

Tracking

With the help of statistics cookies, we can better customise the content and services of our website to your interests and needs. For statistics and analyses, we use the product Matomo for statistics and analyses.

External link warning

Die Nutzung dieses Teildienstes erfordert ihre Einwilligung in die Verarbeitung zusätzlicher personenbezogener Daten durch einen selbständigen Verantwortlichen: Matterport Inc., 352 E. Java Drive, Sunnyvale, CA 94089, USA. Es gelten folgende Datenschutzhinweise: https://matterport.com/de/node/44. Mit der Einwilligung durch Klick auf „Ok“ kann auch eine Übermittlung von personenbezogenen Daten in ein Land außerhalb der Europäischen Union erfolgen. Die Einwilligung ist freiwillig. Eine Ablehnung führt zu keinen Nachteilen. Eine erteilte Einwilligung kann jederzeit mit Wirkung für die Zukunft widerrufen werden.

Ich bin damit einverstanden, dass bei Nutzung dieses Teildienstes zusätzliche personenbezogene Daten verarbeitet werden. Dabei verarbeitete Datenkategorien: technische Verbindungsdaten des Serverzugriffs (IP-Adresse, Datum, Uhrzeit, abgefragte Seite, Browser-Informationen), Daten zur Erstellung von Nutzungsstatistiken und Daten über die Nutzung der Website sowie die Protokollierung von Klicks auf einzelne Elemente. Zweck der Verarbeitung: Auslieferung von Inhalten, die von Dritten bereitgestellt werden. Rechtsgrundlage für die Verarbeitung: Ihre Einwilligung nach Art. 6 (1) a DSGVO, Art. 49 DSGVO. Verantwortlicher für die Datenverarbeitung Matterport Inc., 352 E. Java Drive, Sunnyvale, CA 94089, USA. Es gilt die Datenschutzerklärung von Matterport Inc.: https://matterport.com/de/node/44.

Visit page ▸